The Trump administration unveiled on Friday what it had termed a bold blueprint to address ever-rising drug prices in the United States, but it was mostly a collection of modest, pro-pharmaceutical industry proposals that would nibble at the margins of the issue and likely put more fiscal pressure on hospitals.
